2MAIN1 R, ST CLAIR EW, BREEDVELD F, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase Ⅲ trial [J]. Lancet, 1999,354(9194) :1932 - 1939.
3ST CLAI EW, VAN DER HEIJDE D, SMOLEN J, et al. Combi- nation of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial [ J]. Arthritis Rheum, 2004,50(11 ) :3432 -3443.
4MAINI RN, BREEDVELD FC, KALDEN JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis[ J]. Arthritis Rheum, 1998, 41(9) :1552 - 1563.
5LANGE U, TEICHMANN J, MULLE LADNER U, et at. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-antibody: a prospective open-label pilot study [ J ]. Rheumatology, 2005, 44 ( 12 ) : 1546 - 1548.
6TARGAN SR, HANAUER SB, VAN DEVENTER SJH. A shortterm study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Corhn's disease[JJ. N Engl J Med, 1997,337 (15) :1029 - 1035.
7HANAUER SB, FEAGAN BG, LICHTENSTIN GR,et al. Maintenance infiliximab for Crohn's disease: the ACCENT I randomized trial[J]. Lancet, 2002,359(9317) :1541 -1549.
8PRESENT DH, RUTGEERTS P, TARGAN S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease[ J]. N Engl J Med, 1999,340 ( 18 ) : 1398 - 1405.
9BRAUN J, BRANDT J, LISTING J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial[ J ]. Lancet,2002,359 (9313 ) : 1187 - 1193.
10VAN DEN BOSCH F, KRUITHOF E, BAETEN D, et al. Randomized double-bllnd comparison of chimeric monoclonal antibody to tumor necrosis factor alpha(infliximab) versus placebo in active spondylarthropathy [ J ]. Arthritis Rheum, 2002, 46 ( 3 ) : 755 -765.
二级参考文献20
1[1]Maini RN,Breedveld FC,Kalden JR,et al.Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis[J].Arthritis Rheum,1998,41:1552.
2[2]Maini R,St Clair EW,Breedveld F,et al.Infliximab (chimeric antitumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:randomized phase Ⅲ trial:attract study group[J].Lancet,1999,354:1932.
3[3]St Clai EW,van der Heijde D,Smolen J,et al.Combination of infliximab and methotrexate therapy for early rheumatoid arthritis:a randomized,controlled trial[J].Arthritis Rheum,2004,50:3432.
4[4]U Lange,J Teichmann,Mulle Ladner U,et al.Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-antibody:a prospective open-label pilot study[J].Rheumatology,2005,44:1546.
5[5]PC Taylor,A Steuer,J Gruber,et al.Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one year delayed addition of Infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis[J].Arthritis rheumatism,2006,54:47.
6[6]Carrasco R,Smith JA,Lovell D.Biologic agents for the treatment of juvenile rheumatoid arthritis:current status[J].Paediatr Drugs,2004,6:137.
7[7]Gerloni V,Pontikaki I,Gattinara M,et al.Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody,infliximab,in persistently active,refractory juvenile idiopathic arthritis:results of an open-label prospective study[J].Arthritis Rheum,2005,52:548.
8[8]Braun J,Brandt J,Listing J,et al.Treatment of active ankylosing spondylitis with infliximab:a randomized controlled multicentre trial[J].Lancet,2002,359:1187.
9[9]Braun J,Brandt J,Listing J,et al.Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis[J].Ann Rheum Dis,2005,64:229.
10[10]Braun J,Baraliakos X,Brandt J,et al.Persistant clinical response to the anti-TNF alpha antibody infiiximab in patients with anylosing spondylitis over 3 years[J].Rheumatology,2005,44:670.
10PREVO0 ML, K UPER HH,VAN'T HOFMA, et al. Modified dis- ease activity scores that include twenty - eight - joint counts. De-velopment and validation in a prospective longitudinal study of pa- tients with rheumatoid arthritis. A rthritis Rheum, 1995,38 (1): 315-324.
